Cediranib
Nonneoplastic Condition
Cancer Research UKSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Nonneoplastic Condition cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
VINCRISTINE SULFATE SWOG Cancer Research Network | Phase 2 | B |
PREDNISONE TABLETS SWOG Cancer Research Network | Phase 2 | B |
FILGRASTIM SWOG Cancer Research Network | Phase 2 | B |
VINBLASTINE SWOG Cancer Research Network | Phase 2 | B |
DACARBAZINE SWOG Cancer Research Network | Phase 2 | B |
View all 15 →
Same molecule, other indications
Cediranib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →